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Abstract
Background: The sensitivity of the PCR reaction makes it ideal for use when identifying potentially novel viral
infections in human disease. Unfortunately, this same sensitivity also leaves this popular technique open to
potential contamination with previously amplified PCR products, or “carry-over” contamination. PCR product carry-
over contamination can be prevented with uracil-DNA-glycosylase (UNG), and it is for this reason that it is
commonly included in many commercial PCR master-mixes. While testing the sensitivity of PCR assays to detect
murine DNA contamination in human tissue samples, we inadvertently discovered that the use of this common
PCR reagent may lead to the production of false-negative PCR results.
Findings: We show here that contamination with minute quantities of UNG-digested PCR product or any negative
control PCR reactions containing primer-dimers regardless of UNG presence can completely block amplification
from as much as 60 ng of legitimate target DNA.
Conclusions: These findings could potentially explain discrepant results from laboratories attempting to amplify
MLV-related viruses including XMRV from human samples, as none of the published reports used internal-tube
controls for amplification. The potential for false negative results needs to be considered and carefully controlled in
PCR experiments, especially when the target copy number may be low - just as the potential for false positive
results already is.
Findings
Carry-over contamination can be prevented by incorporat-
ing uracil instead of thymine into the PCR product, then
treating with uracil-DNA-glycosylase (UNG) prior to initi-
ating subsequent PCR reactions [1]. The UNG degrades
DNA containing uracil, thereby degrading contaminating
PCR products while leaving non-uracil DNA (ie. target
DNA) intact. This method is so effective that several
major brands of Taq and Taq master-mixes include this
enzyme and replace dTTP with dUTP. In addition the
enzyme is sold separately and as part of kits designed to
prevent carry-over contamination.
Xenotropic Murine leukemia virus Related Virus
(XMRV) was isolated from patients with prostate cancer
in 2006, and since that time many reports have either
identified XMRV or the highly related murine leukemia
viruses (MLVs) in various patient cohorts. However, many
reports have been unable to find either of these types of
viruses. Mice, particularly strains of mice used in labora-
tory research, carry 20-40 copies of MLV-type viruses.
Therefore MLV-type viral DNA detected in patient sam-
ples could be due to actual MLV infection of patient tissue
or contamination of patient samples with mouse DNA.
We developed an assay to detect femtogram level contam-
ination of murine DNA in human DNA samples. This
sensitivity is necessary because MLV-related viruses found
in human populations seem to be present at very low
levels. Therefore low levels of murine DNA contamination
could give rise to false-positive results.
Use of Uracil-DNA-glycosylase inhibits amplification of
legitimate target DNA in the presence of low levels of
PCR carry-over contamination
We developed an assay to detect contaminating mouse
DNA in human tissue samples using the Gene Expression
master-mix from Applied Biosystems (Life Technologies
Corp.). This master-mix is routinely employed by labs
that carry out Taqman gene expression assays, and it
contains uracil-DNA-glycosylase and dUTP to prevent
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tial PCR product contamination is achieved by a two-
minute incubation at 50°C prior to inactivation of
the enzyme during the initial denaturation of the PCR
reaction. When testing to confirm that PCR carry-over
would be eliminated, we inadvertently discovered that
contamination with as little as 10 picoliters of PCR pro-
duct was able to inhibit amplification of legitimate, albeit
low copy number target (Figure 1a). To determine both
the specificity as well as the effectiveness of the inhibition
of amplification of legitimate target, we intentionally con-
taminated mouse DNA with PCR product generated
using the Gene Expression master-mix. As shown in Fig-
ure 1b, when we attempted to amplify two unrelated tar-
gets from 80 nanograms of mouse DNA, deliberate
contamination with a third unrelated PCR product
(mouse mitochondrial DNA), resulted in significant inhi-
bition of amplification, even when the amount of PCR
product added was just one nanoliter. Furthermore,
when PCR product that was the same as the target reac-
tion was deliberately spiked into the DNA samples and
the PCR was performed with a master-mix containing
UNG, it almost completely inhibited amplification from
60 ng of legitimate target, even at a final dilution of 1:25,
000 and 1:25 million (Figure 1c and 1d, respectively).
Therefore accidental cross-contamination with previously
g e n e r a t e dP C Rp r o d u c tc a ns i g n ificantly inhibit legiti-
mate target amplification, even when the true target is
present at a very high copy number, and the contamina-
tion is minute.
Primer-dimers from previously generated reactions can
also inhibit legitimate target amplification, regardless of
the presence of uracil-DNA-glycosylase
Presumably inhibition of the PCR reaction is due to the
competition for genomic DNA target binding between the
primers and degraded PCR products. Based upon this rea-
soning we tested if primer-dimers generated from a nega-
tive control PCR reaction could inhibit subsequent PCR
amplification. We performed this experiment using a mas-
ter-mix with and without UNG, hypothesizing that the
presence of primer-dimers may be sufficient to inhibit
PCR amplification. For this experiment we intentionally
contaminated mouse DNA with PCR primer-dimers gen-
erated from a PCR reaction using either a UNG- or non-
UNG-containing master-mix. The negative PCR reaction
was able to inhibit the subsequent PCR reaction at a 10
-5
dilution if the same primers were used in the subsequent
reaction, but they did not inhibit amplification of an unre-
lated target (Figure 2a). There was no difference between
UNG and non UNG master-mixes (Figure 2a and 2b).
Given that the primer-dimers of the negative PCR reaction
Figure 1 PCR contamination inhibits legitimate target amplification. a) PCR to amplify mouse mitochondrial DNA was optimized to detect
from 60 ng to 10 fg of mouse DNA. The reaction was intentionally contaminated with previously generated mouse mitochondrial DNA PCR
product. b) The PSMA mouse transgene PCR was intentionally contaminated with PCR products from the mouse mitochondrial DNA PCR and
the PSMA PCR. c) Mouse mitochondrial PCR product was diluted from 10
-2 to 10
-6. These dilutions were used to contaminate a subsequent
mouse mitochondrial PCR. d) The PSMA PCR product was diluted from 10
-2 to 10
-10. The dilutions were used to contaminate a subsequent
PSMA PCR. Human LNCaP DNA and water were run as negative controls and 60 ng of mouse DNA was used as a positive control. All PCR
products, including the PCR products used to contaminate the reactions, were amplified with ABI Gene Expression Master-mix containing UNG.
The results demonstrate inhibition of amplification of large copy numbers of legitimate PCR target when contamination with minute quantities
of the same or different previously generated PCR product was present.
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Page 2 of 7Figure 2 Primer-dimers and UNG degradation products can inhibit PCR amplification. a) The negative control reactions (water and PCR
reagents, but no DNA) from the mouse mitochondrial DNA PCR and the PSMA transgene PCR were diluted from 10
-2 to 10
-5. Both sets of dilutions
were used to contaminate a PCR for the PSMA transgene. All reactions were amplified with the ABI Gene Expression Master-mix (containing UNG).
b) The same experiment was conducted except the NEB Taq Polymerase and buffer was used (no UNG in the PCR for both generation of the
primer-dimers and subsequent PCR). NEB Taq is less efficient than ABI Taq at amplifying the target for the lower band in the PSMA transgene PCR,
however inhibition by contaminating primer-dimers is the same regardless of PCR mix. c) The PSMA transgene PCR product and negative control
were amplified with the ABI Gene Expression Master-mix and gel purified to remove primer-dimers. These products as well as non-purified PSMA
transgene PCR product and negative control (that contain primer-dimers) were used to contaminate a subsequent PSMA transgene PCR. The
results indicate that amplification of legitimate PCR target is significantly inhibited by contamination with previously generated negative control
reactions using the same primers, regardless of the presence or absence of UNG. It also indicates that the UNG degradation products can weakly
inhibit amplification and the UNG degradation products and primer-dimers can completely inhibit PCR amplification.
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Page 3 of 7were able to effectively inhibit subsequent PCR reactions,
we then tested if it was just the primer-dimers in the UNG
containing PCR that provide the inhibition or if the
degraded PCR amplicon was also capable of inhibiting the
subsequent PCR reaction. By gel isolating the UNG incor-
porated PCR product to remove the primer-dimers, and
then spiking (10
-2 dilution) this into a fresh PCR we were
able to demonstrate that this weakly inhibited the sub-
sequent PCR (Figure 2c).
Primer dimers from previously generated reactions
demonstrate a strong inhibitory effect on legitimate
target amplification of an MLV-carrying plasmid
Next we wanted to examine the extent of primer-dimer
inhibition of PCR product formation when specifically
amplifying MLVs. We performed a PCR on plasmid DNA
containing the Gag region of an MLV using primers
within this Gag region. We started with 2 × 10
6 copies (6
pg) of plasmid DNA and contaminated this PCR with dif-
ferent dilutions of either unrelated target primer-dimers
(PSMA transgene) or Gag PCR primer-dimers from pre-
vious PCR reactions. As seen in Figure 3a, the unrelated
target primer-dimers do not inhibit PCR product forma-
tion whereas contamination with Gag PCR primer-dimers
completely inhibits PCR product formation up to 10
-5
dilution and demonstrates weak inhibition of PCR product
formation through 10
-9 dilution.
MLVs previously found to be present in patient sam-
ples have been observed at very low levels. Therefore we
wanted to examine the inhibitory effect that minute
levels of primer-dimer contamination (10
-7 dilution) can
have on Gag PCR product formation from MLVs that are
present at low copy number. Figure 3b demonstrates that
contamination of MLV present at 200, 000 copies or less
with 10
-7 dilution of Gag PCR primer-dimers from a pre-
vious PCR reaction almost completely inhibits PCR pro-
duct formation. This data suggests that contamination
with extremely small quantities of primer-dimers gener-
ated from previous PCR reactions can inhibit PCR pro-
duct formation, thus leading to false negative results.
Taken together, these data suggest that inhibition of
legitimate target occurs from UNG-digested PCR products
or from contamination with primer-dimers from a pre-
vious PCR reaction, regardless of the presence of UNG.
Thus contamination from any previous PCR samples can
result in either false positives (which may or may not be
detected in the negative control depending upon the sam-
ples that are contaminated and whether UNG is used) or
false negatives which will not be detected using standard
PCR controls.
Discussion and Conclusions
As these results could potentially explain some of the dis-
crepancies in amplification of MLV-related viruses from
different laboratories, we surveyed these publications to
attempt to determine if the authors used UNG-containing
master-mixes. Of concern, despite the importance of the
actual PCR methods used to amplify these potentially
novel viruses, we were unable to determine the type of
T a qo rm a s t e r - m i xu s e di n1 1o f3 8p u b l i c a t i o n s .O ft h e
remaining 27 publications, 13 studies used Taq or master-
mixes likely containing UNG (it was present in 8 studies
[2-9] and possibly used in the remaining 5 studies [10-14]
that we examined). Therefore contamination at either the
individual sample level or in the PCR reaction itself could
have inhibited amplification of legitimate target, especially
if the target is found at low levels. Additionally, as shown
in Figure 2, regardless of the presence of UNG, PCR can
be inhibited if there is even a minute amount of contami-
nation from previous (negative) PCR reactions.
Based on our data, we could speculate that low levels of
PCR product contamination may not be sufficient to sig-
nificantly block amplificationo ft h ep o s i t i v ec o n t r o li n
these reactions, especially if the positive control is the tar-
get cloned into a plasmid and present at a high copy num-
ber. In the majority of the studies commented on in this
manuscript, the positive control used was an XMRV plas-
mid, and most papers were not clear about the amount of
plasmid used for control amplification. Therefore, amplifi-
cation of the high copy number positive control could
occur while samples positive for a low copy number virus
could be inhibited by carry-over PCR contamination.
To circumvent the potential for PCR inhibition, a posi-
tive control included in each PCR reaction is necessary to
confirm that the PCR is not inhibited. To accomplish this,
a synthetic target template with identical primer-binding
sites but different size could be constructed, and spiked
into each test sample. This would result in potential
amplification of two bands: one band to detect the target
DNA and the other to detect the synthetic target. In addi-
tion, the copy number of the synthetic target spiked into
the test samples would need to be at the level of detection
of the assay, so as any inhibition would result in lack of
amplification. None of the 38 MLV-related publications
we examined used internal PCR controls. Given the data
presented in this manuscript, we would propose that in
cases such as the debate regarding the existence of novel
infectious viruses, failure to find a virus is not the equiva-
lent of evidence against its existence. The potential for
false negative results needs to be considered and carefully
controlled in PCR experiments, just as the potential for
false positive results already is.
Methods
DNA extraction
Human LNCaP cell line DNA was extracted with the
DNeasy
® Blood & Tissue Kit (Qiagen). DNA from mouse
tails was extracted with the Wizard SV Genomic DNA
Bacich et al. BMC Research Notes 2011, 4:457
http://www.biomedcentral.com/1756-0500/4/457
Page 4 of 7purification system (Promega). Approval for mouse work
was given by the University of Pittsburgh IACUC, under
protocol #1991385A, and the work was performed
according to internationally accepted guidelines. In order
to remove primer-dimers from the PSMA PCR product
and negative control, the bands of the PCR product and
negative control were cut from a 0.8% agarose gel. The
GENECLEAN
® I IK i t( Q b i o g e n e )w a su s e dt op u r i f yt h e
samples per manufacturer’s instructions. Five microliters
of the isolation products were electrophoresed on a 1.5%
agarose gel to confirm the purified PCR and lack of
primer-dimers.
Mouse mitochondrial DNA, PSMA transgene, and
MLV-Gag PCR
All primer sequences are listed in Table 1.
Mitochondrial PCR: 60 ng of mouse DNA was amplified
in a 25 μL reaction containing 12.5 μL 2× Gene Expression
Master-Mix (Applied Biosystems), 0.5 μM Mouse mito F
primer, 0.5 μM Mouse mito R primer, and 9.5 μLo fw a t e r .
Two microliters of 30 ng/μL mouse DNA was added the
reaction. The following cycle conditions were used: 50°C
for 2 minutes (UNG incubation), 94°C for 10 minutes
(AmpliTaq Gold Enzyme Activation), and 40 cycles of 95°C
for 15 seconds and 60°C for 1 minute. The reactions were
Figure 3 Primer-dimers from previously generated reactions demonstrate a strong inhibitory effect on legitimate target amplification
of MLV Gag region. a) The negative control reactions (water and PCR reagents but no DNA) from the PSMA PCR and MLV Gag PCR were
diluted as shown. Both sets of dilutions were used to contaminate a PCR for MLV Gag. The MLV Gag PCR used Titanium Taq Polymerase and
buffer and the PSMA PCR used NEB Taq Polymerase and buffer, with both PCRs being non-UNG containing. b) A negative control reaction
(water and PCR reagents but no DNA) from the MLV Gag PCR was diluted 1 × 10
-7. This PCR, which used non-UNG containing Titanium Taq
Polymerase and buffer, was used to contaminate a subsequent MLV Gag PCR. The MLV-plasmid was used in decreasing copy number, as
indicated.
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Page 5 of 7carried out in an Eppendorf Mastercycler personal thermo-
cycler. The expected size of the PCR product is ~230 bp.
PCR reactions were run on a 1.5% agarose/TBE gel.
Gag PCR: Varying amounts of plasmid DNA was ampli-
fied in a 25 μL reaction containing 2.5 μL 10× Titanium
Taq PCR Buffer (Clonetech), 0.2 uL Titanium Taq (Clone-
tech), 0.2 mM dNTPs, 0.5 μM MLV Gag F primer, 0.5 μM
MLV Gag R primer, and 19.8 μL of water. The following
cycle conditions were used: 94°C for 1 minutes, 40 cycles
of [95°C for 30 seconds and 68°C for 30 seconds], 68°C for
3 minutes. The reactions were carried out in an Eppendorf
Mastercycler personal thermocycler. The expected size of
the PCR product is ~500 bp. PCR reactions were run on a
1.4% agarose/TBE gel.
PSMA transgene PCR: The PSMA PCR contains 2 sets
of primers to amplify two unrelated targets from PSMA
transgenic mice (the transgene and genomic control
sequence). Sixty to eighty nanograms of transgenic
mouse DNA was amplified in a 25 μL reaction containing
12.5 μL 2× Gene Expression Master-Mix (Applied Bio-
systems), 1 μM S49, 1 μMI N T A ,1μM S1368, 1 μM
AS2015, 6.5 μL of water, and 2 μL3 0n g / μlt o4 0n g / μL
mouse DNA. The following cycle conditions were used:
50°C for 2 minutes (UNG incubation), 94°C for 10 min-
utes (AmpliTaq Gold Enzyme Activation), 35 cycles of
94°C for 30 seconds, 58°C for 30 seconds, and 72°C for
45 seconds. The expected product sizes are ~600 bp and
~250 bp and were electrophoresed on a 1.5% agarose/
TBE gel.
The PSMA PCR was also amplified with non-UNG
containing taq. Sixty nanograms of transgenic mouse
DNA was amplified in 25 μL reaction containing 0.5 U
Taq DNA Polymerase, 10× ThermoPol Reaction Buffer
(New England BioLabs, Inc.), 0.4 mM dNTP (dATP,
dTTP, dCTP, and dGTP), 1 μMS 4 9 ,1μMI N T A ,1μM
S1368, and 1 μM AS2015. The following cycle conditions
were used: 94°C for 5 minutes, 35 cycles of 94°C for 30
seconds, 58°C for 30 seconds, and 72°C for 45 seconds.
Negative PCR products (only water added to the PCR
reaction) of the mouse mitochondrial PCR, PSMA PCR,
and Gag PCR were also diluted 10
-2 through 10
-11 and
used to simulate contamination of subsequent PCR reac-
tions. PCR products ranged from 4 ng/μl (PSMA PCR
lower band) to 10 ng/μl for all other reactions, prior to
dilution for use in simulated contamination experiments.
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